Aurobindo Receives Approval For Fosinopril Sodium, Hydrochlorothiazide Tablets
Generic equivalent of Bristol Myers Squibb's Monopril HCT
Aurobindo Pharma has received final approval for Fosinopril Sodium and Hydrochlorothiazide Tablets (USP 10/12.5mg and 20/12.5mg) from the FDA.
Fosinopril Sodium and Hydrochlorothiazide Tablets USP 10/12.5mg and 20/12.5mg are the generic equivalent to Monopril HCT Tablets 10/12.5mg and 20/12.5mg of Bristol Myers Squibb.
The Fosinopril Sodium and Hydrochlorothiazide Tablets are indicated for hypertension and fall under the Cardio Vascular System therapeutic segment.
Aurobindo manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's product portfolio is spread over six therapeutic/product areas encompassing Antibiotics, Anti- Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an extensive R&D set-up. The company is headquartered at Hyderabad, India.
Related Insight
Suppliers Directory
Haselmeier - Self-Injection Devices
Haselmeier is dedicated to meeting the self-injection needs of pharmaceutical manufacturers and patients.
Suppliers
World Courier - Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry
For over 40 years, World Courier has set the standard for worldwide time- and temperature-sensitive transportation services to the pharmaceutical industry. World Courier works with customers to ensure regulatory compliance and supply chain integrity, and to identify and deliver the best logistical solutions for each individual study or consignment.
Suppliers
Zuellig Pharma Specialty Solutions Group - Regional Clinical Trials Management (CTM) Solutions
Zuellig Pharma Specialty Solutions Group (SSG) is a pioneering regional consultancy and bio-logistic services division of Zuellig Pharma Asia Pacific. Strategically based in Singapore at the heart of Asia, SSG leverages Zuellig Pharma’s cutting-edge Regional Distribution Center (RDC) and pan-Asia coverage in 14 countries to provide customized, value-added bio-logistics for pharmaceutical, clinical trials, medical devices, diagnostics and other related companies.
Suppliers
Rovi CM / Rovi Alcala - Research, Development, Manufacturing and Marketing Services
The larger branch of Rovi Group is a fully-integrated Spanish specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of small molecules and speciality biologic drugs. The company was founded in 1946 and the group is quoted on the Madrid Stock Market since 2007. Revenues from 2010 were €158,6 M and takes count with over 800 employees. Due to our flexibility, transparency, expertise and constant dedication, we work hard to make every client feel like our most important one.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Make time for science with the Rocket
Published by Genevac
White Papers
Pressure Mounts for Patient Access to Investigational Drugs
Published by CenterWatch
White Papers
A New Approach to Outsourced Drug Development
Published by INC Research
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.